Extemporaneous Preparation of 20 mg/mL Ganciclovir in Artificial Tears in Comparison with Sterile Water for Ophthalmic Administration: Formulation and Stability Study
暂无分享,去创建一个
J. Suksiriworapong | J. Leanpolchareanchai | Somsiri Sukavatcharin | P. Simaroj | Patamaporn Tangteerakoon | P. Supapsophon
[1] Nantana Nuchtavorn,et al. A Rapid Stability Indicating HPLC Method for Determination of Quetiapine Fumarate in Tablets and Extemporaneous Formulations , 2021, Pharmaceutical Chemistry Journal.
[2] Ajay Sharma,et al. Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use , 2021, Journal of clinical medicine.
[3] Sarfaraz K. Niazi,et al. Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances , 2016, Handbook of Pharmaceutical Manufacturing Formulations, Second Edition.
[4] S. Arshinoff,et al. Role of rheology in tears and artificial tears , 2020, Journal of cataract and refractive surgery.
[5] N. A. Epshtein. System Suitability Requirements for Liquid Chromatography Methods: Controlled Parameters and their Recommended Values (Review) , 2020, Pharmaceutical Chemistry Journal.
[6] M. R. Hilmi,et al. Evaluation of 18 artificial tears based on viscosity and pH , 2020 .
[7] Ganciclovir , 2019, Reactions Weekly.
[8] P. Aragona,et al. Physicochemical Properties of Hyaluronic Acid–Based Lubricant Eye Drops , 2019, Translational vision science & technology.
[9] N. Koizumi,et al. Stability, safety, and pharmacokinetics of ganciclovir eye drops prepared from ganciclovir for intravenous infusion , 2019, Japanese Journal of Ophthalmology.
[10] Margaret L. Wells,et al. Validation of Chromatographic Methods , 2019, Ewing’s Analytical Instrumentation Handbook, Fourth Edition.
[11] L. Power,et al. ASHP Guidelines on Handling Hazardous Drugs , 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[12] S. Sugita,et al. Diagnostic efficacy of real-time PCR for ocular cytomegalovirus infections , 2018, Graefe's Archive for Clinical and Experimental Ophthalmology.
[13] Asad F. Durrani,et al. Cytomegalovirus keratitis , 2018, Current opinion in ophthalmology.
[14] A. Bron,et al. Estimating basal tear osmolarity in normal and dry eye subjects. , 2018, Contact lens & anterior eye : the journal of the British Contact Lens Association.
[15] S. Rudaz,et al. Long-term stability of ganciclovir in polypropylene containers at room temperature , 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[16] N. Keorochana,et al. Efficacy and safety of an extemporaneous preparation of 2% ganciclovir eye drops in CMV anterior uveitis , 2017, BMJ Open Ophthalmology.
[17] N. Koizumi,et al. The effect of topical application of 0.15% ganciclovir gel on cytomegalovirus corneal endotheliitis , 2016, British Journal of Ophthalmology.
[18] C. J. Liu,et al. Long-Term Topical Ganciclovir and Corticosteroids Preserve Corneal Endothelial Function in Cytomegalovirus Corneal Endotheliitis , 2016, Cornea.
[19] S. Teoh,et al. Efficacy and safety of topical ganciclovir in the management of cytomegalovirus (CMV)-related anterior uveitis , 2016, Journal of Ophthalmic Inflammation and Infection.
[20] Haixia Liu,et al. Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a 3-month, multicenter, active-controlled, randomized trial , 2015, Clinical ophthalmology.
[21] L. Suntornsuk,et al. Stability indicating MEKC method for the determination of gliclazide and its specified impurities. , 2015, Journal of pharmaceutical and biomedical analysis.
[22] Tsing-Hong Wang,et al. Clinical outcomes in cytomegalovirus-positive Posner-Schlossman syndrome patients treated with topical ganciclovir therapy. , 2014, American journal of ophthalmology.
[23] N. Koizumi,et al. Clinical features and management of cytomegalovirus corneal endotheliitis: analysis of 106 cases from the Japan corneal endotheliitis study , 2014, British Journal of Ophthalmology.
[24] Chien-Chia Su,et al. Topical ganciclovir treatment in patients with cytomegalovirus endotheliitis receiving penetrating keratoplasty , 2013, Clinical & experimental ophthalmology.
[25] H. K. Kim,et al. A Case of CMV Endotheliitis Treated with Intravitreal Ganciclovir Injection , 2013, Korean journal of ophthalmology : KJO.
[26] K. Basavaiah,et al. Development and Validation of RP-HPLC Method for the Determination of Ganciclovir in Bulk Drug and in Formulations , 2012 .
[27] Chi-Chun Lai,et al. Intravitreal loading injection of ganciclovir with or without adjunctive oral valganciclovir for cytomegalovirus anterior uveitis , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.
[28] S. Chee,et al. Clinical features of cytomegalovirus anterior uveitis in immunocompetent patients. , 2008, American journal of ophthalmology.
[29] N. Koizumi,et al. Cytomegalovirus as an etiologic factor in corneal endotheliitis. , 2008, Ophthalmology.
[30] C. Noppawinyoowong,et al. Chemical Stability and Sterility of Frozen Ganciclovir Injections , 2008 .
[31] J. Colin. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes , 2007, Clinical ophthalmology.
[32] F. Rozenberg,et al. Diagnosis and treatment of cytomegalovirus iridocyclitis without retinal necrosis , 2006, British Journal of Ophthalmology.
[33] Xianshun Chen,et al. Effect of Ganciclovir on the Hydrolytic Degradation of Poly(lactide-co-glycolide) Microspheres , 2006, Journal of biomaterials applications.
[34] E. Domingo,et al. Progress in Drug Research , 2003, Progress in Drug Research.
[35] E. Villarreal. Current and potential therapies for the treatment of herpesvirus infections. , 2001, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[36] A. Bright,et al. The composition and interfacial properties of tears, tear substitutes and tear models , 1993 .
[37] L. Mole,et al. Extended stability of ganciclovir for outpatient parenteral therapy for cytomegalovirus retinitis. , 1992, Journal of acquired immune deficiency syndromes.
[38] R M Hill,et al. Buffering in human tears: pH responses to acid and base challenge. , 1989, Investigative ophthalmology & visual science.
[39] M. Motolko,et al. The effect of pH and osmolarity on the ability of tolerate artificial tears. , 1981, American journal of ophthalmology.
[40] L. Carney,et al. Human tear buffering capacity. , 1979, Archives of ophthalmology.
[41] J. E. Terry,et al. Human tear osmotic pressure: diurnal variations and the closed eye. , 1978, Archives of ophthalmology.
[42] D. Brossard. Methodological guidelines for stability studies of hospital pharmaceutical preparations Part 1 : liquid preparations , 2022 .